1. Home
  2. GOSS vs OFIX Comparison

GOSS vs OFIX Comparison

Compare GOSS & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GOSS
  • OFIX
  • Stock Information
  • Founded
  • GOSS 2015
  • OFIX 1987
  • Country
  • GOSS United States
  • OFIX United States
  • Employees
  • GOSS N/A
  • OFIX N/A
  • Industry
  • GOSS Biotechnology: Pharmaceutical Preparations
  • OFIX Medical/Dental Instruments
  • Sector
  • GOSS Health Care
  • OFIX Health Care
  • Exchange
  • GOSS Nasdaq
  • OFIX Nasdaq
  • Market Cap
  • GOSS 586.6M
  • OFIX 562.0M
  • IPO Year
  • GOSS 2019
  • OFIX N/A
  • Fundamental
  • Price
  • GOSS $2.94
  • OFIX $14.55
  • Analyst Decision
  • GOSS Strong Buy
  • OFIX Strong Buy
  • Analyst Count
  • GOSS 4
  • OFIX 5
  • Target Price
  • GOSS $8.50
  • OFIX $21.50
  • AVG Volume (30 Days)
  • GOSS 3.3M
  • OFIX 489.1K
  • Earning Date
  • GOSS 11-06-2025
  • OFIX 11-06-2025
  • Dividend Yield
  • GOSS N/A
  • OFIX N/A
  • EPS Growth
  • GOSS N/A
  • OFIX N/A
  • EPS
  • GOSS N/A
  • OFIX N/A
  • Revenue
  • GOSS $40,237,000.00
  • OFIX $809,030,000.00
  • Revenue This Year
  • GOSS N/A
  • OFIX $3.86
  • Revenue Next Year
  • GOSS $30.65
  • OFIX $5.57
  • P/E Ratio
  • GOSS N/A
  • OFIX N/A
  • Revenue Growth
  • GOSS N/A
  • OFIX 4.84
  • 52 Week Low
  • GOSS $0.66
  • OFIX $10.24
  • 52 Week High
  • GOSS $2.98
  • OFIX $20.73
  • Technical
  • Relative Strength Index (RSI)
  • GOSS 76.74
  • OFIX 66.28
  • Support Level
  • GOSS $2.41
  • OFIX $14.47
  • Resistance Level
  • GOSS $2.71
  • OFIX $15.03
  • Average True Range (ATR)
  • GOSS 0.19
  • OFIX 0.40
  • MACD
  • GOSS 0.04
  • OFIX -0.09
  • Stochastic Oscillator
  • GOSS 96.37
  • OFIX 44.90

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About OFIX Orthofix Medical Inc. (DE)

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Share on Social Networks: